Sevilla

• Mepolizumab and in-office nasal polypectomy in patients with chronic rhinosinusitis (CRS). A three arm study. Recruiting
  2023-505426-34-01 6 2023-12-18 chronic rhinosinusitis (CRS)
• Multicenter, randomized, double-blind, parallel-group clinical trial to evaluate the efficacy and safety of Safinamide versus Rasagiline in … Recruiting
  2023-503713-29-00 6 2023-12-13 Fatigue symptoms associated with Parkinson´s Disease.
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 7 2023-12-01 participants with isolated methylmalonic acidemia (MMA) due to methylm
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER) Recruiting
  2022-502060-21-00 6 2023-10-19 Haemophilia A
• Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting
  2023-505385-28-00 4 2023-10-19 male or pre/post-menopausal women age ≥ 18 years with locally advanced
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo i … Recruiting
  2024-510959-35-00 4 2023-09-07 Parkinson's disease
• A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or … Recruiting
  2022-501508-82-00 3 2023-08-23 Solid Tumors
• First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting
  2022-502645-99-00 7 2023-08-09 MTAP-deleted Advanced or Metastatic Solid Tumors
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici … Recruiting
  2023-507171-22-00 9 2023-06-21 Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
• Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA … Recruiting
  2024-519194-19-00 7 2023-06-06 Chronic lymphocytic leukemia (CLL)
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in R/R PCNSL Recruiting
  2024-513312-95-00 7 2023-05-30 Part B+C. Primary central nervous system lymphoma (PCNSL)
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations

Showing 649–672 of 1,630 trials